



Europäisches Patentamt
European Patent Office
Offic européen des brevets



Publication number: **0 654 270 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: **94118298.2**

(51) Int. Cl.⁶: **A61K 33/00, A61K 33/14,
A61K 7/48**

(22) Date of filing: **21.11.94**

(30) Priority: **22.11.93 DE 4339750
22.11.93 DE 4339751**

(43) Date of publication of application:
24.05.95 Bulletin 95/21

(84) Designated Contracting States:
AT CH DE ES FR GB GR IT LI NL PT SE

(71) Applicant: **Blener, Hans, Prof. Dr.
Hellmannstrasse 21
D-81479 München (DE)**

(72) Inventor: **Blener, Hans, Prof. Dr.
Hellmannstrasse 21
D-81479 München (DE)**

(54) Preparation for the treatment of acne, seborrheic dermatitis and other skin diseases.

(57) The present invention provides a composition of matter which has been demonstrated to be a very effective treatment for acne, seborrheic dermatitis and related skin diseases when applied to and contacted with affected skin areas, while avoiding the disadvantages and complications attendant to more established treatments. The composition comprises a synthetic mixture of salts which, when dissolved in a solvent such as water, is ionically composed primarily of a mixture of sodium and magnesium cations and chloride and sulfate anions, and which is preferably free of added Zinc. More specifically, the salt mixture according to the present invention comprises the following range of composition in grams/kilogram of salt mixture in the ionic state, the balance being water of hydration:

I.

CATIONS (g/kg salt mixture)		ANIONS (g/kg salt mixture)	
Sodium	150 to 380	Chloride	150 to 750
Magnesium	10 to 90	Sulfate	20 to 200
Calcium	1 to 30	Hydrogen Carbonate	1 to 5
Potassium	0.5 to 35	Carbonate	0.1 to 2

The composition may be applied to the affected areas of the skin as a solution, i.e., as a bath, moist swab or spray, or more preferably in combination with a suitable carrier such as to form a gel, salve, shampoo or a liquid or solid soap. The composition may also be used in combination with known therapeutic agents for treatment of skin diseases, and vanishes very quickly from the skin due to a high absorption by the skin.

EP 0 654 270 A1

Background of the InventionField of the Invention

- 5 The invention concerns a topical skin preparation for the treatment of acne, seborrheic dermatitis and other skin diseases.

Description of Related Art

- 10 Acne is a well known and common skin disease. It has very different forms as well as grades of severity, from the so-called "pubertary pimples" i.e., a simple acne vulgaris, extending to the more dangerous forms such as acne conglobate, which can lead to severe disfigurements of the skin. It is estimated that about one quarter of all young people in the industrialized countries suffer from acne with a culmination age at 15-18 years. The disease acne seems to be generally on the increase. According to a
15 Swiss study, the percentage of acne patients at the University Hospital of Basle increased by ten times from 1920 to 1980. While the maximum age formerly was 25 years, acne patients 50 years of age are as common today. Women of advanced age are clearly affected stronger than men. It can be assumed that the reason is the increasing stress of the skin by environmental influences and improper cosmetics.

- Since acne generally is not life endangering and is regarded by some as a kind of pubertary
20 consequence, only a small part of the people with acne have regular medical treatment. Yet a significant percentage of the population is plagued by this disease. Both disregarding it, as well as excessive and improper treatment, can lead to irreversible scars and changes of the skin, and consequent adverse effects to quality of life.

- To a large extent, the aforementioned is also true for seborrheic dermatitis and other skin diseases in
25 their different forms such as herpes, from simple irritations of the skin up to severe and irreversible changes of epidermis. For distinguishing of these diseases and in order to define their grade, dermatology uses defined terms which can be measured or counted to a high degree. Acne in its different forms such as acne aestivalis, fulminans, necroticans, cosmetica etc. is mostly defined by papules, pustules, blackheads and whiteheads, while seborrheic dermatitis and related skin diseases are generally characterized by itching,
30 scales and erythema.

- There are basically two possibilities for the therapy of acne, seborrheic dermatitis and other related skin diseases: Topical (exterior) treatment and oral treatment which is effective via the metabolism. The oral treatment is principally used only for very severe forms of acne, since retinoids and related active agents may have very strong side effects. In addition, women are endangered during their pregnancy. But even the
35 topical remedies used up to now are not totally safe when applied at the concentration necessary for the desired therapeutic effect. Antibiotic preparations, mainly used for fighting secondary infections, are generally subject to prescription. In addition, benzoylperoxide, which is the topical remedy most used, is by no means as harmless as it would be desirable for at least the treatment of young people. In addition to its suspected carcinogenic effect established in tests with animals, it is very aggressive, and its main effect
40 consists of the oxidation of the upper skin layers like a chemical scalpel, thereby chemically isolating these layers and causing irritation. The same applies for salicylic acid which is used to dissolve the skin by its keratolytic effect. Generally it can be stated that up to now no remedy is available with both good efficacy and skin tolerability.

- It is known that salt solutions can have manifold, mainly positive effects on the skin. Well-known is the
45 shrinking of the skin in ocean water when swimming for a long time, which is caused by osmotic effects. In some cases, upon frequent bathing in sea water, a slight reduction of acne and less itching with seborrheic dermatitis have been observed. This therapeutic effect, however, is negligibly weak and limited to isolated cases.

- The effect of the Dead Sea waters on psoriasis has been therapeutically proven since ancient times. In
50 connection with this treatment, spontaneous healings of acne have also been observed, but in a much too small number to justify such treatment.

 In U.S. Patent 4,943,432, a synthetic salt mixture for the treatment of psoriasis is described. This salt mixture has the following preferred ionic composition:

Magnesium	20 -285	Chloride	20 -750
Sodium	11 -266	Bromide	0.2 - 29
Calcium	2 -235	Sulfate	0.2 - 22
Potassium	2 - 95	Borate	0.05 - 14
Strontium	0.02 -10.5	Silicate	0.02 - 14
Iron	0.02 - 8.5	Fluoride	0.001 - 11
Aluminum	0.001 - 6.0	Iodide	0.001 -9.5
Zinc	0.001 - 2.5	Carbonate	0.0002 -9.0
Lithium	0.001 - 2.0	Hydrogen-carbonate	0.0001 -8.5

Psoriasis is treated with extremely good results using this salt mixture, either as a bath solution or topically applied in the form of a gel. Yet, therapeutic practice has shown that, contrary to the good healing effect on psoriasis, other skin diseases such as acne and seborrheic dermatitis are not influenced as much as would be desired.

Testing has established that, contrary to psoriasis, the effect of the salt mixtures described in the above-mentioned patents was statistically ineffective for treatment of acne and seborrheic dermatitis with a bathing treatment. When such a salt mixture was used gelified with cellulose ether, it also proved to be statistically ineffective for treatment of these conditions.

Accordingly, an object of the invention is to provide a salt mixture composition for the treatment of acne, seborrheic dermatitis and other related skin diseases which, contrary to the treatments known so far, combines a high specific efficacy while avoiding overall adverse effect to the skin and physiology.

SUMMARY OF THE INVENTION

The present invention provides a composition of matter which has been demonstrated to be an effective treatment for acne, seborrheic dermatitis and related skin diseases when applied to and contacted with affected skin areas, while avoiding the disadvantages and complications attendant to established treatments as described above. The composition comprises a synthetic mixture of salts which, when dissolved in a solvent such as water, is ionically composed primarily of a mixture of sodium and magnesium cations and chloride and sulfate anions, and which is preferably free of added Zinc. More specifically, the salt mixture according to the present invention comprises the following approximate range of composition in grams/kilogram of salt mixture in the ionic state, the balance being water of hydration:

I.

CATIONS (g/kg)		ANIONS (g/kg)	
Sodium	150 to 380	Chloride	150 to 750
Magnesium	10 to 90	Sulfate	20 to 200
Calcium	1 to 30	Hydrogen Carbonate	1 to 5
Potassium	0.5 to 35	Carbonate	0.1 to 2

The composition may be applied to the affected areas of the skin as a solution, i.e., as a bath, moist swab or spray, or more preferably in combination with a suitable application medium such as to form a gel, salve, shampoo or a liquid or solid soap.

The invention also provides a method for treating skin diseases comprising topically applying to the affected skin areas a therapeutic salt composition solution comprising a mixture of:

- from about 1 to 30% by weight of a salt composition containing, in the ionic state, a mixture comprising sodium, magnesium, calcium, potassium, chloride, sulfate, hydrogen carbonate and carbonate ions, said ions constituting at least about 97.5% by weight of the ionic content of said salt composition;
- from about 0.05 to about 10% by weight of a therapeutic agent at least partially soluble in said solution and effective for treatment of said skin disease; and
- a solvent for said salt composition.

DETAILED DESCRIPTION OF THE INVENTION

The composition of the present invention may be characterized as being essentially free of organic impurities such as bitumens, oil tars, sewage residues and organic residues as are found in natural salt solutions, e.g., Dead Sea waters. The composition may be further characterized as composed primarily, e.g., at least about 97.5% by weight (exclusive of water of hydration), of a mixture of water soluble salts including sodium chloride, calcium chloride or sulfate, potassium chloride or sulfate, magnesium chloride or sulfate, sodium hydrogen carbonate and sodium carbonate, each mixed in suitable proportions to give rise to compositions having a formulation in the ionic state as described above. In a more preferred embodiment of the invention, the salt mixture is of the formula above and also includes a source of strontium ions, e.g., strontium chloride and/or a source of bromide ions, e.g., sodium bromide such that at least about 99.5% by weight of the mixture (exclusive of water of hydration) has the following composition in grams/kilogram in the ionic state:

CATIONS (g/kg salt mixture)		ANIONS (g/kg salt mixture)	
Sodium	267 to 320	Chloride	450 - to 600
Magnesium	30 to 40	Sulfate	60 - 120
Calcium	5 to 15	Hydrogen Carbonate	3 - 4.2
Potassium	6 to 14	Bromide	1 - 2.5
Strontium	0.1 to 0.3	Carbonate	0.3 - 0.7

The salt mixtures of this invention differ in a number of important respects from those described in U.S. Patent 4,943,432 discussed above. Most notable is the higher content of sodium and sulfate ions and lower content of magnesium and calcium ions associated with the mixtures of the present invention. In addition, the mixture of the present invention is preferably free of added Zinc, and more preferably is also free of added iodide, fluoride, silicate, borate, lithium, aluminum and iron ions which contribute to the efficacy of salt mixtures used to treat psoriasis but which, for reasons not presently understood, have been found to be of no therapeutic effect and even detract from the efficacy of salt mixtures used to treat skin disorders such as acne and seborrheic dermatitis.

In a more preferred embodiment of the invention, the content of sodium chloride constitutes at least about 50% by weight of the salt mixture, more preferably at least about two thirds (67%) by weight of the mixture and the content of sodium ions in the mixture is preferably in excess of 270 grams/kilogram of salt mixture, more preferably in the range of from about 275 to 300 grams/kilogram of salt mixture. It has been found that as a result of the inclusion of sodium in the composition at these levels, the therapeutic effect with respect to acne and seborrheic dermatitis increases dramatically while the therapeutic effect towards psoriasis is found to decrease.

The salt mixtures of the invention are most conveniently applied to the skin as a solution dissolved in a suitable solvent such as water, a lower alcohol or a polyol such as glycerol, or a mixture of two or more of these. Preferably the solvent is distilled or deionized water, which may also contain an alcohol or a water soluble polyol such as glycerol, alone or combined with a suitable carrier or application medium such as to form a gel, an ointment, a salve, a shampoo, or a liquid or solid soap. The concentration of the salt mixture in the solvent or in the application medium will generally range from about 1 to about 30% by weight, more preferably from about 2 to about 15% by weight and most preferably from about 2.5 to about 12% by weight.

Gels or ointment compositions may be conveniently prepared by mixing the salt solution with from about 0.5 to 3% by weight of a natural or synthetic gum or gelling colloid additives as are known in the art, and permitting the mixture to gel. Particularly preferred gelling additives are cellulose esters or ethers. Such compositions may also contain up to about 30% by weight of other additives such as lanolin or glycerin which provide a smooth feel to the skin. Shampoos and soaps may be prepared by formulating the salt solutions with conventional shampoo or soap ingredients, e.g., surface active agents such as ionic or non-ionic surfactants, fatty alcohols, builders, quaternary ammonium salts, fatty esters and fatty amides normally used in such compositions. These compositions may also contain other additives such as preservatives, dyes, perfumes and like conventional additives.

In addition to the therapeutic effect exhibited by the compositions of this invention with respect to the treatment of acne and seborrheic dermatitis, these compositions also demonstrate a remarkable absorbency by the skin, particularly when applied as a solution or as a gel. Thus, the compositions may be used as a carrier medium for known therapeutic agents which are effective for the treatment of not only acne and

seborrheic dermatitis, but also other skin conditions such as herpes or psoriasis. The therapeutic agent should be at least partially soluble in the solvent and may be dissolved in the solvent in relatively small concentrations, because it is quickly and efficiently transported into and through the skin when topically applied. Thus, any skin irritations which might occur as a side effect from application of these therapeutic agents at a higher concentration are minimized. The salt composition also produces a softening effect on the skin which tends to counteract adverse skin reactions to these therapeutics.

Conventional therapeutic anti-acne and anti-dermatitis agents which may be included in the composition include hormones, antibiotics, antiseborrheics and antikeratotics, which are at least partially soluble in the solvent used to prepare the solution. These should be added in amounts such that any normal skin irritation which may be caused by their use is minimized, i.e., generally from about 0.05% by weight to about 10% by weight, more preferably from about 1 to 7% by weight. Examples of suitable therapeutic agents include resorcinol, ibuprofen piconol, resorcinolmonoacetate, chlorohexidine, benzoyl peroxide, salicylic acid, fumaric acid, vitamin A acid, hexachlorophene, acelainic acid, and glycyrrhetic acid and their salts, sulfonamides, colloidal sulfur, ichthyol pyrrithion, selenium derivatives, and the like, as well as antibiotics such as erythromycin or tetracyclines.

Other known active therapeutic ingredients which may be included in the composition at the above levels for the treatment of herpes and other viral infections include virustatica or viracides such as aciclovir, idoxuridin, tromantadin, podophylotoxin, vidarabin and combinations thereof.

Still other therapeutic agents which may be included in the composition include skin conditioners such as lanolin and germ extracts.

The following examples and therapeutic data are illustrative of the invention.

EXAMPLE 1

A therapeutic composition was prepared by dry mixing the following ingredients (pharmaceutical grade):
 553.4 grams Sodium chloride (NaCl)
 106.3 grams Magnesium chloride ($MgCl_2 \cdot 6 H_2O$)
 92.7 grams Magnesium sulfate ($MgSO_4$)
 25.8 grams Calcium chloride ($CaCl_2 \cdot 2 H_2O$)
 15.8 grams Potassium chloride (KCl)
 4.1 grams Sodium hydrogencarbonate ($NaHCO_3$)
 1.2 grams Sodium bromide (NaBr)
 0.7 grams Sodium carbonate (Na_2CO_3)

A solution was formed by dissolving the above salt mixture in 9,000 mls of deionized water to provide a concentration of dissolved solids of 8% by weight. This solution was then formed into a gel by thoroughly mixing it with 1.5% by weight of Hydroxyethylcellulose and 0.07% by weight of a preservative, and permitting the resultant mixture to form a gel.

EXAMPLE 2

A shampoo was prepared by mixing the salt mixture described in Example 1 with a conventional shampoo formulation containing a mixture of anionic lauryl sulfate surfactants, cocoamide, a protein hydrolysate, a quaternary ammonium compound and water. The shampoo was adjusted to a pH of 6.0 by addition of citric acid and contained 8% by weight of dissolved inorganic salt solids.

Clinical tests were conducted as follows:

A. Acne Treatment with Gel

In a controlled study with 100 patients (average age 19.2 years; acne symptoms since an average of 4.4 years), the therapeutic efficacy of the salt gel preparation for the treatment of acne was examined. The gel preparation of Example 1 was applied as a thin layer to the skin once a day for a period of six weeks. The patients received either the salt gel (n = 75) or only a placebo gel without active salt ingredients (n = 25) which was not otherwise distinguishable by color or odor from the active gel. At the beginning of therapy as well as two, four and six weeks after, the number of pustules, papules, open and closed comedones was counted on each patient. After six weeks, an additional evaluation of compatibility/tolerance and efficacy was made, separately by patients and physicians.

In the Verum group, a significant reduction of the number of pustules, papules and comedones (both open and closed) was demonstrated after six weeks compared to the beginning of therapy ($p = 0.001$); a

significant improvement of the clinical status was already evident after 14 days in the Verum group ($p=0.05$). In the Placebo group, there were no significant improvements of the single symptoms; thus the number of pustules, papules, open and closed comedones was highly significantly lower in the Verum group than in the Placebo group after 6 weeks ($p=0.001$). The number of pustules, papules, open and closed comedones was reduced after 6 weeks to 9 - 25% of the original values in the Verum group, while the symptoms in the Placebo group remained practically unchanged with 70 - 99% of the original values.

For the single symptom "pustules" there was even a deterioration of the start values in the Placebo group: After 6 weeks, the number of pustules was about 120% of the original number.

In the Verum group, efficacy and compatibility/tolerance were judged to be very good or good in all cases, both by patients and physicians; in the Placebo group, both patients and physicians judged the efficacy to be poor to bad, but the compatibility/tolerance was judged to be very good.

B. Seborrheic Dermatitis Treatment with Gel

In a controlled study with 66 patients suffering from seborrheic dermatitis of varying degrees of the face and upper part of the body (average age 36 years), the therapeutic efficacy of the gel of the present invention was evaluated. The gel preparation of Example 1 was applied as a thin layer to the affected areas of the skin once a day for a period of four weeks. The patients received either the active salt gel of Example 1 ($n=54$) or a placebo gel without the active salt ingredients ($n=12$), which was not otherwise distinguishable by color or odor from the active gel. Control examinations of the affected skin areas took place at the beginning of the therapy (week 0) as well as after 2 weeks (week 2) and 4 weeks (week 4). At the beginning of the therapy as well as at the examinations after 2 and 4 weeks, the symptoms "itching", "erythema" and "scales" were defined by discreet parameters as follows: 0 = none; 1 = little; 2 = medium and 3 = severe. In addition, the percentage reduction of the sum scores of the symptoms in relation to the scores at the beginning of the therapy were evaluated. A therapeutical effect was defined when the reduction of the symptom scores fell below 50% of the value at the beginning of the therapy.

The progress of the therapy was evaluated by the change in symptoms as documented in Tables 1-3.

TABLE 1(a)

5 Degree of Severity of the Symptom Itching
Verum Group

10	Time	Sum	Average Value	Sta. dev.	Test	Level
	Week 0	117	2,14	0,73	W0 ag. W2	***
15	Week 2	23	0,43	0,63	W2 ag. W4	n.s.
	Week 4	1	0,04	0,04	W0 ag. W4	***

TABLE 1(b)

20 Degree of Severity of the Symptom Itching
Placebo Group

25	Time	Sum	Average Value	Sta. dev.	Test	Level
30	Week 0	28	2.33	0.62	W0 ag. W2	n.s.
	Week 2	26	2.17	0.69	W2 ag. W4	n.s.
35	Week 4	19	1.58	1.58	W0 ag. W4	*

TABLE 2(a)

40 Degree of Severity of the Symptom Erythema
Verum Group

45

50

55

	Tim	Sum	Average Value	Sta. dev.	Test	Level
5	Week 0	81	1,50	0,67	W0 ag. W2	n.s.
	Week 2	54	1,0	0,51	W2 ag. W4	**
	Week 4	13	0,24	0,00	W0 ag. W4	***

TABLE 2 (b)

Degree of Severity of the Symptom Erythema

Placebo Group

	Time	Sum	Average Value	Sta. dev.	Test	Level
20	Week 0	27	2.25	0.43	W0 ag. W2	n.s.
	Week 2	27	2.25	0.43	W2 ag. W4	n.s.
	Week 4	21	1.75	0.83	W0 ag. W4	n.s.

TABLE 3(a)

Degree of Severity of the Symptom Scales
Verum Group

	Time	Sum	Average Value	Sta. dev.	Test	Level
40	Week 0	62	1.15	0,45	W0 ag. W2	**
	Week 2	19	0.35	0,55	W2 ag. W4	n.s.
	Week 4	3	0.06	0,23	W0 ag. W4	***

TABLE 3 (b)

Degree of Severity of the Symptom Scales

Placebo Group

	Time	Sum	Average Value	Sta.dev.	Test	Level
5	Week 0	14	1.17	0,45	W0 ag. W2	n.s.
	Week 2	15	1.25	0,55	W2 ag. W4	n.s.
	Week 4	17	1.17	0,23	W0 ag. W4	n.s.

10

Abbreviations

15	Sta.dev.	=	Standard deviation
	Wx	=	Examination date after Week x
	ag.	=	Against
	n.s.	=	No significant difference
20	*	=	Significant difference, p= 0.05
	**	=	Very significant difference, p= 0.01
	***	=	Highly significant difference, p= 0.001

25

The data in Tables 1-3 show a very clear and highly significant reduction of the average values for all three symptoms in the Verum group between the beginning and end of the therapy. In contrast, the Placebo group shows no significant changes in any of these symptoms.

30 C. Treatment of Scale Seborrheic Dermatitis with Shampoo

In a controlled study with 55 patents suffering from seborrheic dermatitis of the hairy scalp (average age 37.4 years), the therapeutic efficacy of the shampoo described in Example 2 was evaluated. The shampoo (8 gms) was applied to wetted hair, lathered into the scalp for a period of 2 minutes, and rinsed.

35 This treatment was repeated once daily for a period of 4 weeks. The patients received either the active shampoo of Example 2 (n=28) or a placebo shampoo (n=27) which did not contain the active salt ingredients but was otherwise identical to the shampoo of Example 2, and which was not otherwise distinguishable by color or odor from the active shampoo. Control examinations of the affected scalp skin areas took place at the beginning of the therapy (week 0) as well as after 2 and 4 weeks as in the case of

40 the gel study described above. These examinations were evaluated using the same criteria and standards as used in the gel evaluations described above, and test results are shown in Tables 4-6.

45

50

55

TABLE 4

Degree of Severity of the Single Symptoms, Verum Group.			
	ITCHING	ERYTHEMA	SCALES
Beginning of Study			
Sum Scores	55	50	37
Average Value	1.96	1.82	1.3
Standard Deviation	0.82	0.77	0.93
Week 2			
Sum Scores	28	26	16
Average Value	1	0.9	0.56
Standard Deviation	0.6	0.59	0.68
Week 4			
Sum Scores	6	6	16
Average Value	0.22	0.22	0.56
Standard Deviation	0.49	0.49	0.5

TABLE 5

Degree of Severity of the Single Symptoms, Placebo Group.			
	ITCHING	ERYTHEMA	SCALES
Beginning of Study			
Sum Scores	42	39	47
Average Value	1.48	1.3	1.63
Standard Deviation	0.78	0.67	0.76
Week 2			
Sum Scores	35	39	43
Average Value	1.22	1.33	1.52
Standard Deviation	0.74	0.78	0.68
Week 4			
Sum Scores	35	37	33
Average Value	1.22	1.26	1.19
Standard Deviation	0.63	0.71	0.47

TABLE 6

Course of Total Scores.			
VERUM GROUP			
Total Score	142	70	28
Average Value	5.07	2.52	1
Standard Deviation	1.69	1.3	1.17
PLACEBO GROUP	BEGINNING OF STUDY	WEEK 2	WEEK 4
Total Score	128	117	105
Average Value	4.4	4.07	3.67
Standard Deviation	1.84	1.83	1.35

Based on the data from Tables 4-6, the Verum group showed a strong reduction of the sum scores and the average values of the total symptoms as well as the single symptoms "itching", "erythema" and "scales". The difference between beginning of the therapy and second week was already significant (probability $p=0.01-0.005$). Between beginning of the therapy and week 4, the difference was highly significant (probability $p=0.001$ or 99%).

There was no significant reduction of the sum scores and the average values in the Placebo group, neither of the general symptoms nor of the single symptoms "itching" and "erythema". Solely the symptom "scales" was less in the Placebo group, compared between start of the therapy and the fourth week. Statistical comparison of the two groups at the three examination dates shows a difference for the symptoms "itching" and "erythema" at the start of the therapy. This means that these symptoms were stronger in the randomized Verum group. Regarding the symptom "scales", there were no significant differences at the start time of the therapy, although the sum scores as well as the average values were higher in the Placebo group than in the Verum group. Yet, there was no statistically significant difference regarding the total sum scores and their average values at the beginning of the clinical study between the two groups. At the end of the study, there were highly significant lower values for all single symptoms and for the total sum scores in the Verum group compared with the Placebo group.

In no single case was there an allergic reaction or any lasting irritation observed with the patients treated with the salt compositions of this invention.

Example 3

The gel composition of Example 1 was prepared except that about 1% by weight of salicylic acid was included in the formulation. The gel was applied and rubbed into human skin. The skin appeared dry to the touch after about 1-2 minutes, indicating that the composition had been effectively absorbed into the skin.

A control gel was prepared also containing 1% by weight of salicylic acid but without inclusion of the salt mixture described in Example 1. After application of the same quantity of the control gel to the skin, the skin remained damp even after 15 minutes, indicating poor absorption of the therapeutic into the skin.

Example 3 illustrates that the salt compositions of the present invention serve as an excellent carrier medium for therapeutic agents. Because of high absorption by the skin, the composition vanishes quickly from the skin thereby carrying the therapeutic agent with it into the skin.

Claims

1. A composition for the treatment of skin diseases by application to affected areas of the skin, said composition prepared by forming a mixture comprising salt components such that the salt components are present in the mixture in the following approximate proportions, expressed as grams/kilogram of salt mixture in the ionic state:

CATIONS (g/kg)		ANIONS (g/kg)	
Sodium	150 to 380	Chloride	150 to 750
Magnesium	10 to 90	Sulfate	20 to 200
Calcium	1 to 30	Hydrogen Carbonate	1 to 5
Potassium	0.5 to 35	Carbonate	0.1 to 2

said composition further characterized as being dissolved in a solvent and as being free of added Zinc.

2. A composition for the treatment of skin diseases by application to the affected areas of the skin comprising the composition of Claim 1 dissolved in water at a concentration within the range of from about 1 to about 30% by weight.
3. A gel comprising the composition of Claim 1 mixed with a natural or synthetic gum or gelling additive sufficient to form a gel.
4. A shampoo comprising the composition of Claim 1 mixed with surface active agents sufficient to form a shampoo.
5. The composition of Claim 1 which is also free of added iodide, fluoride, silicate, borate, lithium, aluminum and iron ions.
6. The composition of Claim 1 which contains sodium ions at a level of at least 270 grams/kilogram of salt mixture.
7. The composition of Claim 1 which further contains from about 1 to 2.5 grams/kilogram of salt mixture of bromide ions.
8. The composition of Claim 1 which further contains from about 0.1 to 0.3 grams/kilogram of salt mixture of strontium ions.
9. The composition of Claim 1 wherein said solvent comprises water and said mixture comprises salt components such that the salt components are present in the mixture in the following proportions, expressed as grams/kilogram of salt mixture in the ionic state:

CATIONS (g/kg)		ANIONS (g/kg)	
Sodium	267 to 320	Chloride	450 to 600
Magnesium	30 to 40	Sulfate	60 to 120
Calcium	5 to 15	Hydrogen Carbonate	3 to 4.2
Potassium	6 to 14	Carbonate	0.3 to 0.7

10. The composition of Claim 9 which further contains from about 1 to 2.5 grams/kilogram of salt mixture of bromide ions.
11. The composition of Claim 9 which further contains from about 0.1 to 0.3 grams/kilogram of salt mixture of strontium ions.
12. The composition of Claim 1 dissolved in water as a carrier medium at a concentration within the, range of from about 2.5 to about 12% by weight.
13. A gel comprising the composition of Claim 12 mixed with a natural or synthetic gum or gelling additive sufficient to form a gel.
14. A shampoo comprising the composition of Claim 12 mixed with surface active agents sufficient to form a shampoo.

15. A method for treating a skin disease comprising contacting the affected skin areas with the composition of Claims 1, 3, 4, 5, 8, 9, 10 or 11.
16. The method of Claim 15 wherein said skin disease is acne.
17. The method of Claim 15 wherein said skin disease is seborrheic dermatitis.
18. A method for treating a skin disease comprising topically applying to the affected skin areas a therapeutic salt composition solution, said solution comprising a mixture of:
- a) from about 1 to 30% by weight of a salt composition containing, in the ionic state, a mixture comprising sodium, magnesium, calcium, potassium, chloride, sulfate, hydrogen carbonate and carbonate ions, said ions constituting at least about 97.5% by weight of the ionic content of said salt composition;
- b) from about 0.05 to about 10% by weight of a therapeutic agent at least partially soluble in said solution and effective for treatment of said skin disease; and
- c) a solvent for said salt composition.
19. The method of Claim 18 wherein said solvent comprises water.
20. The method of claim 19 wherein said salt components are present in said composition in the following proportions, expressed as grams/kilogram of salt mixture in the ionic state:

CATIONS (g/kg)		ANIONS (g/kg)	
Sodium	150-380	Chloride	150-750
Magnesium	10-90	Sulfate	20 to 200
Calcium	1 to 30	Hydrogen Carbonate	1 to 5
Potassium	0.5 to 35	Carbonate	0.1 to 2

21. The method of claim 20 wherein said salt composition is free of added Zinc.
22. The method of claim 21 wherein said composition is mixed with a natural or synthetic gum or gelling additive sufficient to form a gel.
23. The method of claim 21 wherein said composition is mixed with surface active agents sufficient to form a shampoo.
24. The method of claim 21 wherein said salt composition is also free of added iodide, fluoride, silicate, borate, lithium, aluminum and iron ions.
25. The method of claim 21 wherein said salt composition contains sodium ions at a level of at least 270 grams/kilograms of salt mixture.
26. The method of claim 21 wherein said salt composition further contains from about 1 to 2.5 grams/kilogram of salt mixture of bromide ions.
27. The method of claim 21 wherein said salt composition further contains from about 0.1 to 0.3 grams/kilogram of salt mixture of strontium ions.
28. The method of claim 20 wherein said mixture comprises salt components such that the salt components are present in the mixture in the following proportions, expressed as grams/kilogram of salt mixture in the ionic state:

CATIONS (g/kg)		ANIONS (g/kg)	
Sodium	267 to 320	Chlorid	450 to 600
Magnesium	30 to 40	Sulfate	60 to 120
Calcium	5 to 15	Hydrogen Carbonate	3 to 4.2
Potassium	6 to 14	Carbonate	0.3 to 0.7

5

10 29. The method of claim 28 wherein said salt mixture further contains from about 1 to 2.5 grams/kilogram of salt mixture of bromide ions.

30. The method of claim 28 wherein said salt mixture further contains from about 0.1 to 0.3 grams/kilogram of salt mixture of strontium ions.

15

31. The method of claim 20 wherein said salt composition is dissolved in water at a concentration within the range of from about 2.5 to about 12% by weight.

20

25

30

35

40

45

50

55



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 94 11 8298
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
X,D	EP-A-0 217 975 (BIENER H.)	1-3,6-8, 12,13, 15-22, 25-27,31	A61K33/00 A61K33/14 A61K7/48
Y	* claims 1,5-8 * * column 2, line 19 - column 3, line 10 * * column 3, line 16 - column 4, line 3 * * claims 1,5-8 *	4,5,14, 23,24	
Y	* column 2, line 19, paragraph 3 - column 3, line 10; claim 10 * * column 3, line 16 - column 4, line 3 * & US-A-4 943 432 ---	4,5,14, 23,24	
X	FR-A-5 799M (BOSSARD F.J.) * claims 1-3; examples 3,4 * * page 1, right column, line 1 - line 9 * ---	1-11,15	TECHNICAL FIELDS SEARCHED (Int. CL. 6)
	WO-A-89 06133 (COMMIN A. -R.) * claims 1,5 * * abstract * ---		A61K
	-/--		
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search VIENNA		Date of completion of the search 30 December 1994	Examiner MAZZUCCO
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	

EPO FORM 1501 01.92 (PM/CO)



EP 94 11 8298

Remark: Although claims 15-31
are directed to a method of
treatment of the human/animal
body (Art. 52(4) EPC) the search
has been carried out and based on
the alleged effects of the
compound/composition

This Page Blank (uspto)